Baxter International Inc
NYSE:BAX

Watchlist Manager
Baxter International Inc Logo
Baxter International Inc
NYSE:BAX
Watchlist
Price: 19.33 USD -0.26%
Market Cap: 9.9B USD

Intrinsic Value

The intrinsic value of one BAX stock under the Base Case scenario is 43.95 USD. Compared to the current market price of 19.33 USD, Baxter International Inc is Undervalued by 56%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

BAX Intrinsic Value
43.95 USD
Undervaluation 56%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation History
Baxter International Inc

What is Valuation History?
Ask AI Assistant
What other research platforms think about BAX?

Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.

Discover External Valuations
Why is BAX valued this way?

Let our AI break down the key assumptions behind the intrinsic value calculation for Baxter International Inc.

Explain Valuation
Compare BAX to

Fundamental Analysis

Company Overview
Loading...
Business Segments
Loading...
Economic Moat
Loading...
Earnings Call
Loading...
Management
Loading...
Contacts
Loading...
Bear Theses

Baxter’s recent supply chain disruptions, combined with ongoing product recalls in its infusion pump portfolio, threaten to erode the company’s reputation for quality and could lead to higher costs and reduced revenue growth in the near term.

The company’s strategic decisions, including the planned spin-off of its renal care and acute therapies segments, risk diverting management’s focus and disrupting operational efficiency, potentially undermining expected synergistic benefits and near-term profitability.

Intensifying competition from established players in dialysis (Fresenius Medical Care) and infusion systems (B. Braun) could pressure Baxter to invest heavily in R&D or pricing strategies, contracting margins and reducing returns on capital.

Bull Theses

Baxter’s diversified portfolio—spanning infusion systems, renal care, and advanced surgery products—positions the firm to capture steady growth, as healthcare providers increasingly seek proven, integrated solutions from a single partner.

The planned separation of certain business lines, such as Baxter’s biopharma solutions business, may unlock shareholder value through more targeted strategic direction and improved capital allocation, amplifying both segments’ profit potential.

With ongoing investments in digital health tools and next-generation infusion technologies, Baxter stands to capitalize on emerging trends in precision medicine and telehealth, enhancing its competitive edge and supporting robust long-term growth.

Show More Less
How do you feel about BAX?
Bearish
Neutral
Bullish
Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Baxter International Inc

Current Assets 6.9B
Cash & Short-Term Investments 1.7B
Receivables 1.8B
Other Current Assets 3.4B
Non-Current Assets 14.1B
PP&E 3.1B
Intangibles 10.2B
Other Non-Current Assets 847m
Current Liabilities 3.8B
Accounts Payable 953m
Accrued Liabilities 1.9B
Short-Term Debt 4m
Other Current Liabilities 875m
Non-Current Liabilities 10.1B
Long-Term Debt 8.7B
Other Non-Current Liabilities 1.3B
Efficiency

Free Cash Flow Analysis
Baxter International Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Baxter International Inc

Revenue
11B USD
Cost of Revenue
-7.2B USD
Gross Profit
3.9B USD
Operating Expenses
-3.2B USD
Operating Income
702m USD
Other Expenses
-1B USD
Net Income
-341m USD
Fundamental Scores

BAX Profitability Score
Profitability Due Diligence

Baxter International Inc's profitability score is 48/100. The higher the profitability score, the more profitable the company is.

ROE is Increasing
Positive 3Y Average ROIC
Healthy Gross Margin
Sustainable 3Y Average Gross Margin
48/100
Profitability
Score

Baxter International Inc's profitability score is 48/100. The higher the profitability score, the more profitable the company is.

BAX Solvency Score
Solvency Due Diligence

Baxter International Inc's solvency score is 39/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Long-Term Solvency
Average D/E
Average Altman Z-Score
39/100
Solvency
Score

Baxter International Inc's solvency score is 39/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

BAX Price Targets Summary
Baxter International Inc

Wall Street analysts forecast BAX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for BAX is 24.55 USD with a low forecast of 15.15 USD and a high forecast of 50.41 USD.

Lowest
Price Target
15.15 USD
22% Downside
Average
Price Target
24.55 USD
27% Upside
Highest
Price Target
50.41 USD
161% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
N/A
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
Shareholder Yield

Current shareholder yield for BAX is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
Lowest
Average
Highest
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y

Ownership

BAX Insider Trading
Buy and sell transactions by insiders

BAX News

Other Videos
What is the Intrinsic Value of one BAX stock?

The intrinsic value of one BAX stock under the Base Case scenario is 43.95 USD.

Is BAX stock undervalued or overvalued?

Compared to the current market price of 19.33 USD, Baxter International Inc is Undervalued by 56%.

Back to Top